233
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

The impact of low-dose aspirin on markers of inflammation and placental function: an ancillary study of the ASPIRIN trial

, , , , &
Pages 6901-6905 | Received 10 Mar 2021, Accepted 10 May 2021, Published online: 20 May 2021
 

Abstract

Objective

To determine the impact of low-dose aspirin (81 mg) on markers of maternal inflammation and placental function.

Setting

Rural Southern India

Population

Nulliparous women with a singleton pregnancy dated by ultrasound who were enrolled in the ASPIRIN (Aspirin Supplementation for Pregnancy Indicated risk Reduction In Nulliparas) Trial.

Methods

We performed a case-control study to elucidate the impact of low dose aspirin (LDA) on markers of placental function and maternal inflammation among women who delivered prematurely compared to term controls in women enrolled in the ASPIRIN trial. Women were prospectively enrolled in an ancillary observational trial wherein maternal serum was collected and measured between 10 to 13 weeks and 17 to 21 weeks of gestation after initiation of aspirin or an identical placebo.

Results

From 2016-18 with a total of 666 n women enrolled in this ancillary trial of whom 269 were selected for analyte analysis. Women who received LDA had lower levels of Alpha Feto-Protein (AFP) at 10 to 13 weeks than women who received placebo (Placebo) (LDA 18.3 ng/mL vs 21.4 ng/mL -P 0.001). AFP was similar between the two groups at 17 to 21 weeks. No other differences were seen in C-Reactive protein or Anti-Mullerian Hormone.

Conclusion

Low-dose aspirin administration lowers AFP early in pregnancy.

Author contributions

RA conceived of the manuscript and wrote the first draft with input from MSS, MKH and SSG. AK, RA, SSV, MSS and SSG oversaw study implementation, data collection and quality monitoring. RA, AK, and MSS performed the statistical analyses. All authors reviewed and approved the final manuscript.

Clinical trial registration

ClinicalTrials.gov, NCT02409680, and the Clinical

Trial Registry-India, CTRI/2016/05/006970.

Reprints: Reprints will not be provided.

Disclosure statement

The authors report no conflict of interest

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.